You'll get the exact copy in the photo
Parameters
- 264 pages
- 10 hours of reading
More about the book
The book presents a groundbreaking strategy for complete cancer treatment through two novel drug compounds, PT162 and PT167, developed by Andreas J. Kesel. These drugs target the Warburg effect, exploiting cancer's reliance on glycolysis due to mitochondrial dysfunction. Both compounds demonstrate significant efficacy in vitro against 60 cancer cell lines, inducing apoptosis by reactivating p53 and disrupting cyclin D1 regulation. The book details the chemistry behind these compounds and their apoptotic mechanisms, offering hope for innovative cancer therapies.
Book purchase
THE POTENTIAL HEALING OF CANCER WITH P53 (RE)ACTIVATORS, Andreas Johannes Kesel
- Language
- Released
- 2023
- product-detail.submit-box.info.binding
- (Hardcover),
- Book condition
- Very Good
- Price
- €33.99
Payment methods
No one has rated yet.
- Title
- THE POTENTIAL HEALING OF CANCER WITH P53 (RE)ACTIVATORS
- Subtitle
- TWO NEW DRUGS EXPLOITING CANCER'S WARBURG EFFECT
- Language
- English
- Authors
- Andreas Johannes Kesel
- Publisher
- tredition
- Released
- 2023
- Format
- Hardcover
- Pages
- 264
- ISBN10
- 3384003128
- ISBN13
- 9783384003126
- Series
- Tags
- Non-Fiction, Health & Medicine, Science & Math, Nature, Natural sciences, Medicine, Chemistry, Nature, Animals, Pharmacology, Biochemistry, Oncology, Organic Chemistry, Molecular Biology, Human Biology, Inorganic Chemistry, Chemotherapy, Pharmacotherapy
- Description
- The book presents a groundbreaking strategy for complete cancer treatment through two novel drug compounds, PT162 and PT167, developed by Andreas J. Kesel. These drugs target the Warburg effect, exploiting cancer's reliance on glycolysis due to mitochondrial dysfunction. Both compounds demonstrate significant efficacy in vitro against 60 cancer cell lines, inducing apoptosis by reactivating p53 and disrupting cyclin D1 regulation. The book details the chemistry behind these compounds and their apoptotic mechanisms, offering hope for innovative cancer therapies.